- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Elscint reorganizes high-tech sales staffs
Elscint has reinforced its reputation for ongoing structural change by again reorganizingits nuclear medicine and CT/MRI sales and marketing groups. Changes announced March 1 are intended to give the units clearlydefined lines of responsibility,
Elscint has reinforced its reputation for ongoing structural change by again reorganizingits nuclear medicine and CT/MRI sales and marketing groups.
Changes announced March 1 are intended to give the units clearlydefined lines of responsibility, according to Donald J. Southard,vice president of sales and marketing. The key appointment isthe selection of John Ariatti as business unit director and actingwestern regional manager for CT/MRI.
Ariatti was formerly director of sales, marketing and customersupport for Otsuka Electronics in Fort Collins, CO. Prior to that,he was MRI marketing director and CT business unit manager forToshiba America Medical Systems.
Elscint Ltd., the parent company of Elscint, Inc., purchasedOtsuka's MRI business. Those assets have been renamed ElscintMR, Inc.
Israel Ohana has departed as nuclear medicine product managerand Southard has temporarily assumed that role. Southard joinedElscint as part of a 1994 restructuring effort, after servingas president and CEO of Serviscope, an independent service organizationin Wallingford, CT.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
